The Asia Pacific cancer biomarker market is touted to be the fastest growing region, evolving at a CAGR of 13.23% over the forecast period of 2019-2027. The improvement in the healthcare infrastructure with government initiatives are the prime drivers propelling the market growth in the region. The key geographies analyzed for the Asia-Pacific region are India, China, Japan, Australia, South Korea and rest of Asia-Pacific.

ASIA PACIFIC CANCER BIOMARKER MARKET 2019-2027

Asia Pacific Cancer Biomarker Market by Profiling Technology (Omic Technology (Genomics, Proteomics, Other Omic Technologies, Imaging Technologies, Immunoassays, Cytogenetic-based Tests) by Biomaker Genetic Biomarkers, Protein Biomarkers, Glyco Biomarkers) by Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Others Cancer Type) by Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment, Other Application) & by Geography
Request free sample

Report Summary

The Asia Pacific cancer biomarker market is touted to be the fastest growing region, evolving at a CAGR of 13.23% over the forecast period of 2019-2027. The improvement in the healthcare infrastructure with government initiatives are the prime drivers propelling the market growth in the region.

The key geographies analyzed for the Asia-Pacific region are India, China, Japan, Australia, South Korea and rest of Asia-Pacific. The economic developments in prime countries such as India and China is expected to largely contribute to the market growth in the near future. Moreover, Huge population base with low per capita income in the region has led to a high demand for affordable treatment options.

Multinational companies are looking forward to investing in developing countries such as Japan, India and China. Thus, many collaborative partnerships and strategic alliances are taking place within the companies in this region, which is also driving the cancer biomarker market in the Asia Pacific region.

Some of the eminent companies in this market include Celgene Corporation, Qiagen N.V., Astellas Pharma Inc., Becton Dickinson and Company, Bristol-Myers Squibb, Clarient, Inc. (Acquired By Neogenomics Laboratories), Diadexus Inc. (Acquired By Diazyme Laboratories), Roche Diagnostics Ltd., Aureon Biosciences, Inc., Agendia N.V., Agilent Technologies, Inc., Beckman Coulter, Sanofi, Abbott Laboratories and Illumina, Inc.

 

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    Table of Contents

    1. RESEARCH SCOPE
      • STUDY GOALS
      • SCOPE OF THE MARKET STUDY
      • WHO WILL FIND THIS REPORT USEFUL?
      • STUDY AND FORECASTING YEARS
    2. RESEARCH METHODOLOGY
      • SOURCES OF DATA
        • SECONDARY DATA
        • PRIMARY DATA
      • TOP DOWN APPROACH
      • BOTTOM-UP APPROACH
      • DATA TRIANGULATION
    3. EXECUTIVE SUMMARY
      • MARKET SUMMARY
      • KEY FINDINGS
        • OMIC TECHNOLOGY GENERATED THE HIGHEST REVENUE IN TERMS OF PROFILING TECHNOLOGY
        • GLYCO BIOMARKERS ARE THE FASTEST GROWING CANCER BIOMARKERS
        • BREAST CANCER HOLDS THE LARGEST MARKET SHARE IN TERMS OF CANCER TYPE
        • DIAGNOSTICS APPLICATION IS THE MAJORLY USED CANCER BIOMARKER APPLICATION
    1. MARKET DYNAMICS
      • MARKET SCOPE & DEFINITION
      • MARKET DRIVERS
        • ADOPTION OF WESTERN LIFESTYLES IN DEVELOPING REGIONS
        • GROWING PREVALENCE ON RESEARCH OF CANCER BIOMARKERS
        • IMPROVED PRECISION AND SPEED OF DIAGNOSIS
        • HIGH INVESTMENT THROUGH GOVERNMENT AND PRIVATE FUNDS IN CANCER RELATED RESEARCH
        • DEVELOPMENT OF HIGHLY SPECIFIC DRUGS
        • GROWTH IN IMPORTANCE OF BIOLOGICAL AND TARGETED DRUG THERAPIES
        • TECHNOLOGICAL ADVANCEMENTS
        • GROWING PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS
      • MARKET RESTRAINTS
        • POOR COMPENSATION STRUCTURES
        • LOW ESTIMATED RATE OF SUCCESSFUL CLINICAL TRIALS OF BIOMARKERS
        • TECHNICAL ISSUES RELATED TO CANCER BIOMARKERS
        • HIGH COST OF DRUG DEVELOPMENT
        • UNCLEAR GOVERNMENT REGULATION AND REIMBURSEMENT POLICIES
      • MARKET OPPORTUNITIES
        • WIDE OPPORTUNITY TO GROW IN PERSONALIZED MEDICATION
        • SUPPORTS ON BIOMARKERS TEST
        • GROWING NUMBER OF CANCER PATIENTS AND GROWING MEDICAL TOURISM IN EMERGING ECONOMIES
        • ADVANCEMENT OF CANCER DRUGS RESEARCH
      • MARKET CHALLENGES
        • LACKING ACCEPTANCE OF THE CANCER BIOMARKER
        • UNFAVORABLE COMPENSATION SITUATION
        • HIGH COST OF DEVELOPING COMPANION DIAGNOSTICS
        • RIGOROUS REGULATORY AGENDA
        • DEARTH OF SKILFUL WORKERS
    1. MARKET BY PROFILING TECHNOLOGY
      • OMIC TECHNOLOGY
      • IMAGING TECHNOLOGIES
      • IMMUNOASSAYS
      • CYTOGENETIC-BASED TESTS
    2. MARKET BY BIOMARKER
      • GENETIC BIOMARKERS
      • PROTEIN BIOMARKERS
      • GLYCO BIOMARKERS
    3. MARKET BY CANCER TYPE
      • LUNG CANCER
      • BREAST CANCER
      • COLORECTAL CANCER
      • PROSTATE CANCER
      • STOMACH CANCER
      • OTHERS CANCER TYPE
    4. MARKET BY APPLICATION
      • DIAGNOSTICS
      • DRUG DISCOVERY AND DEVELOPMENT
      • PROGNOSTICS
      • RISK ASSESSMENT
      • OTHER APPLICATION
    5. KEY ANALYTICS
      • PORTER’S FIVE FORCE ANALYSIS
        • THREAT OF NEW ENTRANTS
        • THREAT OF SUBSTITUTE PRODUCT
        • BARGAINING POWER OF BUYER
        • BARGAINING POWER OF SUPPLIERS
        • INTENSITY OF COMPETITIVE RIVALRY
      • KEY BUYING CRITERIA
        • PRICING
        • EFFICACY
        • APPLICATION AND EFFECTIVENESS
      • PATENT ANALYSIS
      • OPPORTUNITY MATRIX
    6. GEOGRAPHICAL ANALYSIS
      • ASIA PACIFIC
        • CHINA
        • INDIA
        • JAPAN
        • SOUTH KOREA
        • AUSTRALIA
        • REST OF APAC
    1. COMPETITIVE LANDSCAPE
      • MARKET SHARE ANALYSIS
      • COMPANY PROFILES
        • ABBOTT LABORATORIES
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • AGENDIA N.V.
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • AGILENT TECHNOLOGIES, INC.
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • AUREON BIOSCIENCES, INC
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • ASTELLAS PHARMA INC.
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • BECKMAN COULTER
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • BECTON DICKINSON AND COMPANY
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • BRISTOL-MYERS SQUIBB
          • COMPANY PROFILES
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • CELGENE CORPORATION
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • CLARIENT, INC. (ACQUIRED BY NEOGENOMICS LABORATORIES)
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • DIADEXUS INC. (ACQUIRED BY DIAZYME LABORATORIES)
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • ILLUMINA, INC.
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • ROCHE DIAGNOSTICS LTD
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • SANOFI
          • COMPANY OVERVIEW
          • PRODUCTS PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • QIAGEN N.V.
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES

    TABLE LIST

    TABLE  1      ASIA PACIFIC CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

    TABLE  2      RECENT RESEARCH ON BIOMARKERS

    TABLE  3      POTENTIAL CLINICAL USE OF  CANCER BIOMARKERS

    TABLE  4      MEDICAL TOURISM PRICES IN US DOLLAR

    TABLE  5      ASIA PACIFIC CANCER BIOMARKER MARKET BY PROFILING TECHNOLOGY 2019-2027 ($ MILLION)

    TABLE  6      ASIA PACIFIC OMIC TECHNOLOGY MARKET 2019-2027 ($ MILLION)

    TABLE  7      ASIA PACIFIC IMAGING TECHNOLOGIES MARKET 2019-2027 ($ MILLION)

    TABLE  8      ASIA PACIFIC IMMUNOASSAYS MARKET 2019-2027 ($ MILLION)

    TABLE  9      ASIA PACIFIC CYTOGENETICS-BASED TESTS MARKET 2019-2027 ($ MILLION)

    TABLE  10    ASIA PACIFIC CANCER BIOMARKER MARKET BY BIOMARKER 2019-2027 ($ MILLION)

    TABLE  11    ASIA PACIFIC GENETIC BIOMARKERS MARKET 2019-2027 ($ MILLION)

    TABLE  12    ASIA PACIFIC PROTEIN BIOMARKERS MARKET 2019-2027 ($ MILLION)

    TABLE  13    ASIA PACIFIC GLYCO BIOMARKERS MARKET 2019-2027 ($ MILLION)

    TABLE  14    ASIA PACIFIC CANCER BIOMARKER MARKET BY CANCER TYPE 2019-2027 ($ MILLION)

    TABLE  15    ASIA PACIFIC LUNG CANCER MARKET 2019-2027 ($ MILLION)

    TABLE  16    ASIA PACIFIC BREAST CANCER MARKET 2019-2027 ($ MILLION)

    TABLE  17    ASIA PACIFIC COLORECTAL CANCER MARKET 2019-2027 ($ MILLION)

    TABLE  18    ASIA PACIFIC PROSTATE CANCER MARKET 2019-2027 ($ MILLION)

    TABLE  19    ASIA PACIFIC STOMACH CANCER MARKET 2019-2027 ($ MILLION)

    TABLE  20    ASIA PACIFIC OTHERS CANCER TYPE MARKET 2019-2027 ($ MILLION)

    TABLE  21    ASIA PACIFIC CANCER BIOMARKER MARKET BY APPLICATION 2019-2027 ($ MILLION)

    TABLE  22    ASIA PACIFIC DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

    TABLE  23    ASIA PACIFIC DRUG DISCOVERY AND DEVELOPMENT MARKET 2019-2027 ($ MILLION)

    TABLE  24    ASIA PACIFIC PROGNOSTICS MARKET 2019-2027 ($ MILLION)

    TABLE  25    ASIA PACIFIC RISK ASSESSMENT MARKET 2019-2027 ($ MILLION)

    TABLE  26    ASIA PACIFIC OTHER APPLICATION MARKET 2019-2027 ($ MILLION)

    TABLE  27    PATENT PRODUCTS WITH THE EXPIRY DATE

    TABLE  28    PATENT PUBLICATIONS RELATED TO  BREAST CANCER 2017

    TABLE  29    PATENT PUBLICATIONS RELATED TO  PROSTATE CANCER 2017

    TABLE  30    PATENT PUBLICATIONS RELATED TO  LUNG CANCER 2017

    TABLE  31    ASIA PACIFIC CANCER BIOMARKER MARKET BY COUNTRY 2019-2027 ($ MILLION)

    TABLE  32    STATE-WISE DISTRIBUTION OF CANCER IN INDIA

    TABLE  33    ESTIMATED MOST COMMON CANCERS DIAGNOSED IN AUSTRALIA 2017

    FIGURES LIST 

    FIGURE  1    ASIA PACIFIC CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

    FIGURE  2    PHARMACOGENOMIC BIOMARKERS INFORMATION IN DRUG LABELING

    FIGURE  3    PERCENTAGE OF PATIENTS INEFFECTIVE FOR PARTICULAR DRUG (%)

    FIGURE  4    ASIA PACIFIC CANCER BIOMARKER MARKET SHARE BY PROFILING TECHNOLOGY 2018 & 2027 (%)

    FIGURE  5    ASIA PACIFIC CANCER BIOMARKER MARKET SHARE BY BIOMARKER 2018 & 2027 (%)

    FIGURE  6    ASIA PACIFIC CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)

    FIGURE  7    ASIA PACIFIC CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)

    FIGURE  8    PORTER’S FIVE FORCE ANALYSIS

    FIGURE  9    ASIA PACIFIC CANCER BIOMARKER MARKET REGIONAL OUTLOOK 2018 & 2027 (%)

    FIGURE  10  CHINA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

    FIGURE  11  INDIA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

    FIGURE  12  JAPAN CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

    FIGURE  13  SOUTH KOREA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

    FIGURE  14  AUSTRALIA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

    FIGURE  15  REST OF APAC CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

    FIGURE  16  MARKET SHARE ANALYSIS OF KEY PLAYERS 2017 (%)

    Segmentation

    1. GEOGRAPHICAL ANALYSIS
      • ASIA PACIFIC
        • CHINA
        • INDIA
        • JAPAN
        • SOUTH KOREA
        • AUSTRALIA
        • REST OF APAC
    1. MARKET BY PROFILING TECHNOLOGY
      • OMIC TECHNOLOGY
      • IMAGING TECHNOLOGIES
      • IMMUNOASSAYS
      • CYTOGENETIC-BASED TESTS
    2. MARKET BY BIOMARKER
      • GENETIC BIOMARKERS
      • PROTEIN BIOMARKERS
      • GLYCO BIOMARKERS
    3. MARKET BY CANCER TYPE
      • LUNG CANCER
      • BREAST CANCER
      • COLORECTAL CANCER
      • PROSTATE CANCER
      • STOMACH CANCER
      • OTHERS CANCER TYPE
    4. MARKET BY APPLICATION
      • DIAGNOSTICS
      • DRUG DISCOVERY AND DEVELOPMENT
      • PROGNOSTICS
      • RISK ASSESSMENT
      • OTHER APPLICATION

    Request Free Sample

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type

      Get In Touch

      Inquire Before Buying

      Customization

      Inkwood Research delivers customized reports as per the client's requirement to provide them with an edge in the competitive market

      Request Customization

      RELATED REPORTS